Back to News
Market Impact: 0.3
Achieve's Cytisinicline Shows 31% Smoking And Vaping Cessation Rate At One Year; Stock Up
Source: Nasdaq
Healthcare & Biotech
Achieve Life Sciences reported new 52-week results from its ORCA-OL trial, saying extended treatment with cytisinicline helped a meaningful proportion of participants quit smoking or vaping, including some who had previously failed a medication. The excerpt provides no response rates or other numerical trial results, limiting assessment of the magnitude and commercial significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ACHV0.75
More News
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump
- Arcus Biosciences prices $250 million stock offering at $17.50
- AstraZeneca says U.S. FDA approves rare kidney disease drug
- UnitedHealth's Earnings Jumped 60%. Is the Comeback Stock a Buy, Sell, or Hold?
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Why is Intuitive Surgical stock tumbling today?